

## The Nomination committee for Dicot AB appointed

**Press release: Uppsala, November 3, 2022. According to decision at the Annual General Meeting of Dicot AB on May 24, 2022, the Nomination committee for the Annual General Meeting on May 23, 2023, shall consist of three members representing the three largest shareholders as of the end of September 2022.**

Based on the above, the Nomination committee for the 2023 Annual General Meeting (AGM) has been appointed with the following three members:

- Bertil Lindkvist
- Tore Robertsson
- Arne Paalberg

The Nomination committee shall submit proposals for decisions regarding the following subjects for the AGM on May 23, 2023:

- a) Election of chairman at the AGM.
- b) Determination of number of board members.
- c) Determination of fees and other compensation for the board and its committees, divided between the chairman and other board members.
- d) Determination of fees for auditors.
- e) Election of board members and chairman of the board.
- f) Election of auditors.
- g) Principles for the Nomination committee's composition and work ahead of the 2024 AGM.

Shareholders who wish to submit proposals to the Nomination committee can do so via e-mail to: [Eva.Sjokvist.Saers@dicot.se](mailto:Eva.Sjokvist.Saers@dicot.se)

In order for the Nomination committee to be able to consider proposals, the proposal must have been received in good time before the AGM, but no later than March 31, 2023.

### **For further information, please contact:**

Elin Trampe, CEO  
Tel: +46 739 80 14 08  
Email: [elin.trampe@dicot.se](mailto:elin.trampe@dicot.se)

### **About Dicot AB**

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is

---

# DICOT

---

to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit [www.dicot.se](http://www.dicot.se).

---